Using new, highly sensitive methods, the researchers detected and visualized how amyloid beta protein—a plaque that builds up in the brains of people with Alzheimer's disease—binds to lecanemab, ...

One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with early-stage disease.

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to Alzheimer's disease.

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

While similar to lecanemab (Leqembi), an earlier FDA-approved infusion, donanemab introduces new possibilities in how Alzheimer’s can be managed—and potentially paused. Donanemab is a ...

Nonetheless, Lilly has submitted donanemab to the US FDA under the ... Its cost-effectiveness deliberations for lecanemab arrive at a price range of between $8,500 and $20,600 for a year's ...

Donanemab works similarly to lecanemab, another promising Alzheimer's drug. Patients on lecanemab need infusions every two weeks, while donanemab is administered once a month. Between his ...

Two disease-modifying treatments have been approved for use in the UK, these are donanemab, and lecanemab. However, they are not available on the NHS. Before a drug can be approved for use in the UK, ...

The new guidelines for the use of monoclonal antibodies (mAbs) published in Neurodegenerative Diseases, serve as exemplary clinical recommendations for clinicians and healthcare providers, supporting ...

At that level, both lecanemab and donanemab act very similarly. "Further work is needed to understand what is most important: binding oligomeric structures or binding amyloid plaques. This is ...